Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The cont
| Condition(s) | Moxibustion, Hematopoietic Stem Cell Transplantation, Hemorrhagic Cystitis, Prevention |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine |
| Who can participate | Inclusion Criteria: 1. Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF); 2. Age: 14-60 years; 3. Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia; severeaplasticanimin, SAA) undergoing allo-HSCT; Exclusion Criteria: 1. refuse to participate in this clinical study; 2. The corresponding skin at the moxibustion site is broken or sensitive; 3. allo-HSCT pretreated with the RIC program; |
| Ages | 14 Years to 60 Years |
| Sex | All |
| Lead sponsor | Yi Zhang |
| Locations | Zhengzhou, Henan, China; Wuhan, Hubei, China; Kunming, Yunnan, China; Hangzhou, Zhejiang, China |
| Start date | 2024-03-21 |
| NCT ID | NCT06198517 |
| Official listing | https://clinicaltrials.gov/study/NCT06198517 |